Frontlight ResearchEarly access
CompletedNo phase
The Cre8™ BTK Post Market Clinical Follow-up Study
Key facts
- Who runs it
- CID S.p.A.
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 12 Apr 2023
- Ended
- 31 Jan 2024
- Type of study
- Observational
- Treatments tested
- Cre8™ BTK
- Record updated
- 22 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (3)Hide the full registry criteria
Who can take part
- Patient has been implanted with at least one Cre8™ BTK device according to the indications described in the Instructions for Use (IFU),
- Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection
Who cannot take part
- Patients treated less than 12 months prior to study start
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cre8™ BTK is a CE marked drug eluting stent, integrally coated with i-Carbofilm, loaded with formulated Sirolimus for the treatment of infrapopliteal peripheral artery disease.
Read full original descriptionShow less
The aim of this post-market retrospective study protocol P32102 is to collect clinical data of patient treated with Cre8™ BTK stent in routine clinical practice.
In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Cre8™ BTK stent at least 12 months prior to the study start.
Treatments tested
- Cre8™ BTK
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sirolimus Drug-eluting Stent for the Treatment of Infrapopliteal Peripheral Artery Disease: Evaluation of Safety and Performance in Everyday Clinical Practice. The Cre8™ BTK Post Market Clinical Follow-up Study.
- Record updated
- 22 October 2026